PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
The Influence of AMPK Subunit Alpha (PRKAA2) Genetic Polymorphisms With Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
1 other identifier
observational
750
0 countries
N/A
Brief Summary
Metformin is a classical oral antidiabetic drug, often recommended to be the first-choice treatment of type 2 diabetes mellitus (T2DM). Based on the previous research on PRKAA2, STK11 and diabetes, this study aimed to investigate the distributive characteristic of PRKAA2 and STK11 polymorphisms and the potential influence of STK11polymorphisms on metformin efficacy among Chinese T2DM patients, discuss the association of PRKAA2 polymorphisms between T2DM patients and healthy subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2013
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedFirst Submitted
Initial submission to the registry
May 11, 2017
CompletedFirst Posted
Study publicly available on registry
May 16, 2017
CompletedMay 16, 2017
May 1, 2017
2 years
May 11, 2017
May 15, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the incidence of T2DM
people whose fasting plasma glucose ≥7.0 mmol/L and/or postprandial plasma glucose ≥11.1 mmol/L is diagnosed with T2DM.
Jan 2014-Dec 2015
Secondary Outcomes (1)
metformin efficacy----the decrease level of HbA1c
Jan 2014-Dec 2015
Study Arms (2)
T2DM patients
Metformin dosages ranged from 500 to 2000 mg per day
healthy subjects
the healthy subjects was not intervened
Interventions
Eligibility Criteria
the study recruited 500 T2DM patients and 250 healthy subjects who meet the enrollment cirterion from Zhengzhou Central Hospital during the period of July 2013 to December 2015 randomly.
You may qualify if:
- diagnosed with T2DM in keeping with the WHO criteria in 1999 \[14\], with fasting blood glucose (FBG) ≥ 7.0mmol ⁄ L and ⁄ or postprandial blood glucose (PBG) ≥ 11.1mmol ⁄ L; not using other antidiabetic drugs within the experimental period.
You may not qualify if:
- other significant illness such as cancer, myocardial infarction, stroke, severe liver, and kidney disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Li Q, Li C, Li H, Zeng L, Kang Z, Mao Y, Tang X, Zheng P, He L, Luo F, Li Z. STK11 rs2075604 Polymorphism Is Associated with Metformin Efficacy in Chinese Type 2 Diabetes Mellitus. Int J Endocrinol. 2017;2017:3402808. doi: 10.1155/2017/3402808. Epub 2017 Jul 9.
PMID: 28775741DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 11, 2017
First Posted
May 16, 2017
Study Start
June 1, 2013
Primary Completion
June 1, 2015
Study Completion
December 1, 2015
Last Updated
May 16, 2017
Record last verified: 2017-05
Data Sharing
- IPD Sharing
- Will not share